The upcoming clinical trial, TECAR Therapy on Pain and Quality of Life in Men With Chronic Prostatitis/Chronic Pelvic Pain Syndrome, sponsored by Middle East University, has been listed as not yet recruiting. This trial aims to assess the effectiveness of TECAR therapy as a medical device intervention for alleviating pain and improving quality of life among men affected by chronic prostatitis and chronic pelvic pain syndrome. This announcement may be of particular interest to healthcare professionals, clinical researchers, and medical device regulators monitoring developments in non-invasive pain management strategies.
In this article
What changed?
The clinical trial is scheduled to evaluate the potential of TECAR therapy, a heat and energy transfer-based medical device treatment, in managing symptoms of chronic prostatitis and chronic pelvic pain syndrome. Although the study has not yet started recruiting participants, this marks an important step towards exploring non-invasive solutions for a condition that significantly impacts male patients’ quality of life.
Regulatory teams may find this news relevant, as it highlights the continued development and evaluation of innovative medical technologies aimed at improving patient care.
What is TECAR therapy?
TECAR therapy, short for Transfer of Energy Capacitive and Resistive, is a medical device intervention designed to stimulate biological tissues through electrical energy and heat. It is commonly used in pain management, rehabilitation, and sports medicine. The therapy claims to accelerate healing processes, enhance tissue oxygenation, and alleviate pain without invasive procedures.
The regulatory review of such therapies often includes assessing their safety, intended performance, and outcomes based on clinical trials like this one.
What does the clinical trial involve?
According to the listing, this study will compare the outcomes of TECAR therapy with a sham therapy group to establish its efficacy and safety. Participants are expected to include men diagnosed with chronic prostatitis or chronic pelvic pain syndrome, a condition characterized by ongoing pain and urinary problems.
The trial’s primary outcomes will focus on measuring pain reduction and improved quality of life (QoL) in the participants. Sham TECAR therapy will serve as a control to ensure rigorous comparison and strengthen evidence. Such controls are critical in validating the performance of the device under investigation.
While no recruitment dates have been provided, clinical researchers and industry professionals should keep a close watch on the progress of this trial for valuable insights into TECAR therapy’s potential applications.
Frequently Asked Questions
- 1. What is the purpose of this clinical trial?
The trial aims to evaluate the effectiveness of TECAR therapy in reducing pain and improving quality of life in men with chronic prostatitis/chronic pelvic pain syndrome. - 2. Who sponsors the trial?
The trial is sponsored by Middle East University. - 3. Is participant recruitment open?
No, recruitment for this trial has not yet started as of now. - 4. What is the role of sham TECAR therapy in the study?
Sham TECAR therapy acts as a control to ensure an unbiased evaluation of the device’s effectiveness. - 5. Where can additional details about this trial be found?
You can learn more at the official ClinicalTrials.gov listing linked below.
Conclusion
This new clinical trial represents another step towards addressing a significant healthcare issue for men with chronic prostatitis and chronic pelvic pain syndrome. While recruitment has yet to begin, the study underscores the growing push to explore effective medical device-led therapies for pain and quality-of-life improvements. Regulatory teams should closely monitor outcomes from such trials to stay informed about potential advancements in medical technology.
Disclaimer
The information provided in this article is intended for professionals in the clinical, regulatory, and quality fields. It is not legal advice. Please consult official sources or experts for specific guidance.
Full announcement details
For full information about the announcement, see the link below.
https://clinicaltrials.gov/study/NCT07324239?term=medical+device